Aviado · Research
Longevity Daily
Thursday, April 16, 2026
Listen
Today's Brief
The day's most important story challenges years of optimism: a major independent review concludes the "breakthrough" anti-amyloid Alzheimer's drugs produce effects too small to matter clinically, landing the same week a Phase 3 semaglutide trial in Alzheimer's reaches a similar verdict. Together they make today's cognitive section essential reading for anyone tracking the dementia prevention landscape. Our Aviado deep-dive resolves a long-standing supplement puzzle — why astaxanthin delivers dramatic results for some and almost nothing for others — and the FDA signals it may finally overhaul how dietary supplements are regulated.
10 stories1 trials1 Aviado original
Cognitive Health & Neuroprotection
'Gamechanger' Alzheimer's Drugs Show No Clinically Meaningful Effect, Major Review Finds
An influential independent review covering the highly promoted anti-amyloid drugs lecanemab and donanemab has concluded their effect on cognitive decline is 'trivial' and 'well below' what would constitute meaningful patient benefit. Professor Edo Richard at Radboud University Medical Centre, a co-author, stated that the analysis found 'no clinically meaningful effect on cognitive decline or dementia severity,' despite both drugs receiving approvals and widespread celebration as breakthroughs. For patients and families navigating treatment decisions, the science underpinning these billion-dollar drugs is significantly weaker than the headlines have suggested. For the broader longevity community, it's a sobering reminder that clearing amyloid plaques from the brain may be necessary but is not sufficient to halt dementia progression.
Read more →Semaglutide Fails to Slow Alzheimer's Progression in Landmark Phase 3 EVOKE Trial
The Phase 3 EVOKE trial — one of the most rigorously designed Alzheimer's studies to date, with biomarker-rich endpoints including MRI, CSF markers, and cognitive composites — found semaglutide did not slow cognitive decline or dementia severity. This stands in stark contrast to observational data from over 1 million patients with type 2 diabetes, where semaglutide was associated with a 40–70% lower risk of first-time Alzheimer's diagnosis versus other diabetes drugs. The disconnect between compelling real-world associations and controlled trial outcomes is a critical calibration for anyone banking on GLP-1s as a dementia prevention strategy.
Read more →New Blood Test Can Signal Alzheimer's Disease Progression Years Before Onset
A new biomarker-based blood test can detect signs of Alzheimer's disease progression years before brain scan changes or cognitive symptoms emerge — part of a rapidly maturing field of blood-based Alzheimer's biomarkers including p-tau217 and GFAP. For health-optimizing readers who already track routine labs, this points toward a near future where a standard blood panel could flag neurological risk decades early, enabling earlier lifestyle and pharmaceutical interventions when they are likely most effective.
Read more →Lonely Seniors Start With Worse Memory — But Decline at the Same Rate as Their Peers
A new study delivers an important correction to the popular narrative that loneliness accelerates dementia: while lonely older adults show significantly worse baseline memory scores, their rate of cognitive decline over time is no faster than non-lonely peers. What this means practically is that loneliness lowers your cognitive starting point — it doesn't necessarily steepen the slope. The implication for longevity-focused readers is that social connection likely matters most as an early protective factor, not only as a brake on decline once it has already begun.
Read more →Supplements & Compounds
Calcium Fructoborate-Phytochemical Blend Improves Recovery, Sleep, and Pain Threshold After Exercise
Participants taking a supplement combining calcium fructoborate with a phytochemical blend experienced significant improvements in pressure pain threshold, sleep quality, recovery time, and post-exercise fatigue in a new study. The findings expand the known profile of calcium fructoborate — previously studied primarily for joint health — into the exercise recovery space. For active readers who monitor post-workout recovery metrics, this is an early but interesting data point worth tracking as more research emerges.
Read more →Why Your Astaxanthin Results Depend Almost Entirely on Your Metabolic Starting Point
New research resolves a long-standing puzzle in the astaxanthin literature: people with elevated inflammation (CRP >2 mg/L), high fasting insulin (>10 μIU/mL), or elevated oxidative stress markers see up to 10x more benefit than those who are already metabolically healthy. If you're in a metabolically compromised group — type 2 diabetes, PCOS, or chronic low-grade inflammation — 6 mg daily taken with a fatty meal can meaningfully reduce IL-6, MDA, and fasting insulin within 8–12 weeks. If your markers are already in the optimal range, expect modest results at best; higher doses (12–20 mg) rarely add meaningful additional benefit.
Read the full Aviado analysis →Research & Papers
Rapamycin, Semaglutide, and Dapagliflozin Will Face Off in the First Head-to-Head Longevity Trial
Researchers at UT Health San Antonio have received funding to test the longevity field's most-discussed drugs — rapamycin, dapagliflozin (an SGLT2 inhibitor), and semaglutide (a GLP-1 agonist) — head-to-head for their ability to prevent intrinsic capacity decline in healthy adults in their 60s. This is the direct comparative trial the field has long needed, moving beyond observational associations to determine which approved drug, if any, meaningfully bends the aging curve in non-diabetic adults. Results are years away, but the trial design alone sets a new benchmark for longevity research rigor.
Read more →Lifestyle & Nutrition
A 15-Minute Smartphone Blood Test Can Map Your Biological Clock in Real Time
Researchers have developed a rapid 15-minute blood test using europium nanoparticles and a standard smartphone to measure melatonin levels and track an individual's real-time circadian phase — originally designed to help astronauts manage disrupted biological rhythms in space. For shift workers, frequent long-haul travelers, or anyone optimizing sleep timing, this technology points toward affordable, portable circadian profiling as a practical health tool. Knowing your precise circadian phase in real time could inform smarter decisions around light exposure, meal timing, and when to take time-sensitive supplements.
Read more →Industry & Policy
GLP-1 Experimentation Has Outrun the Science — and That's a Problem
A New York Times opinion piece maps the explosive off-label experimentation with GLP-1 drugs — microdosing for longevity, self-experimentation for menopause symptoms, unapproved compounded formulations for bodybuilding — happening almost entirely outside clinical trials and the formal healthcare system. The authors argue the science cannot keep up, and the evidence base for most of these uses simply doesn't exist yet, even as real-world systemic effects accumulate. For readers already using or considering GLP-1s off-label, this is a useful reality check on what we actually know versus what the internet currently believes.
Read more →FDA Signals a Long-Overdue Overhaul of Dietary Supplement Regulation
The FDA has signaled a significant reassessment of its dietary supplement regulatory framework, framing a public meeting around fundamental questions: which ingredients qualify, how safety is evaluated, and what modernization should look like. For supplement consumers and brands alike, changes here could mean stricter ingredient vetting, more rigorous safety standards, and clearer labeling requirements. The current framework, largely unchanged since the Dietary Supplement Health and Education Act of 1994, has long been criticized as inadequate for today's $60 billion market.
Read more →